Michail S Kukharsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/38416/publications.pdf

Version: 2024-02-01

23 papers 610 citations

686830 13 h-index 24 g-index

30 all docs 30 docs citations

30 times ranked

762 citing authors

#	Article	IF	CITATIONS
1	In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches. Medicinal Research Reviews, 2021, 41, 2804-2822.	5.0	13
2	Long non-coding RNA NEAT1_1 ameliorates TDP-43 toxicity in in vivo models of TDP-43 proteinopathy. RNA Biology, 2021, 18, 1546-1554.	1.5	27
3	A bioisostere of Dimebon/Latrepirdine delays the onset and slows the progression of pathology in FUS transgenic mice. CNS Neuroscience and Therapeutics, 2021, 27, 765-775.	1.9	4
4	Retinal Damage in Amyotrophic Lateral Sclerosis: Underlying Mechanisms. Eye and Brain, 2021, Volume 13, 131-146.	3.8	14
5	Alterations in the nigrostriatal system following conditional inactivation of \hat{l} ±-synuclein in neurons of adult and aging mice. Neurobiology of Aging, 2020, 91, 76-87.	1.5	24
6	Long non-coding RNA Neat1 regulates adaptive behavioural response to stress in mice. Translational Psychiatry, 2020, 10, 171.	2.4	38
7	Low Level of Expression of C-Terminally Truncated Human FUS Causes Extensive Changes in the Spinal Cord Transcriptome of Asymptomatic Transgenic Mice. Neurochemical Research, 2020, 45, 1168-1179.	1.6	3
8	Behavioural impairments in mice of a novel FUS transgenic line recapitulate features of frontotemporal lobar degeneration. Genes, Brain and Behavior, 2019, 18, e12607.	1.1	10
9	Stem cells in human breast milk. Human Cell, 2019, 32, 223-230.	1.2	53
10	Protective paraspeckle hyper-assembly downstream of TDP-43 loss of function in amyotrophic lateral sclerosis. Molecular Neurodegeneration, 2018, 13, 30.	4.4	70
11	Genetic inactivation of alpha-synuclein affects embryonic development of dopaminergic neurons of the substantia nigra, but not the ventral tegmental area, in mouse brain. PeerJ, 2018, 6, e4779.	0.9	6
12	Detection of autoantibodies to potentially amyloidogenic protein, gamma-synuclein, in the serum of patients with amyotrophic lateral sclerosis and cerebral circulatory disorders. Doklady Biochemistry and Biophysics, 2017, 472, 64-67.	0.3	3
13	Chronically stressed or stress-preconditioned neurons fail to maintain stress granule assembly. Cell Death and Disease, 2017, 8, e2788-e2788.	2.7	38
14	Intracerebral Injection of Metal-Binding Domain of AÎ 2 Comprising the Isomerized Asp7 Increases the Amyloid Burden in Transgenic Mice. Neurotoxicity Research, 2016, 29, 551-557.	1.3	28
15	Early lethality and neuronal proteinopathy in mice expressing cytoplasm-targeted FUS that lacks the RNA recognition motif. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 402-409.	1.1	17
16	Calcium-responsive transactivator (CREST) protein shares a set of structural and functional traits with other proteins associated with amyotrophic lateral sclerosis. Molecular Neurodegeneration, 2015, 10, 20.	4.4	25
17	Gamma-carboline inhibits neurodegenerative processes in a transgenic model of amyotrophic lateral sclerosis. Doklady Biochemistry and Biophysics, 2015, 462, 189-192.	0.3	7
18	C9ORF72 hexanucleotide repeat expansion in ALS patients from the Central European Russia population. Neurobiology of Aging, 2015, 36, 2908.e5-2908.e9.	1.5	12

#	Article	IF	CITATIONS
19	The Y-Box Binding Protein 1 Suppresses Alzheimer's Disease Progression in Two Animal Models. PLoS ONE, 2015, 10, e0138867.	1.1	24
20	Gamma-synuclein binds synaptic vesicles but does not interact with SNARE-complex proteins. Doklady Biochemistry and Biophysics, 2014, 456, 108-110.	0.3	1
21	Chronic Administration of Dimebon does not Ameliorate Amyloid-Î ² Pathology in 5xFAD Transgenic Mice. Journal of Alzheimer's Disease, 2013, 36, 589-596.	1.2	26
22	Therapeutic Effect of Exogenous Hsp70 in Mouse Models of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 425-435.	1.2	106
23	Chronic Administration of Dimebon Ameliorates Pathology in TauP301S Transgenic Mice. Journal of Alzheimer's Disease, 2013, 33, 1041-1049.	1.2	48